HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...
As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback